Cancer Care Guidelines Get a Reality Check: Adapting Supportive Care to Real-World Resources

Cancer does not strike equally, and neither does the care that follows it. In low- and middle-income countries, the burden of cancer is climbing steeply, marked by high incidence, high prevalence, and mortality-to-incidence ratios that dwarf those seen in wealthier nations. Patients often arrive at clinics late, with advanced disease and crushing symptom burdens, because access to care is limited and health disparities run deep. In these settings, supportive care—the management of the physical, psychological, and social fallout of cancer and its treatment—is not a luxury. It is the difference between completing therapy and abandoning it, between preventable suffering and a dignified quality of life. Yet the clinical guidelines meant to guide that care are overwhelmingly written in high-income countries, prioritizing efficacy and safety over affordability and accessibility, and frequently failing to reflect what is actually possible in resource-constrained environments.

A new discussion paper published in Supportive Care in Cancer by an international team led by researchers at Flinders University in Australia, working under the auspices of the Multinational Association of Supportive Care in Cancer (MASCC), confronts this problem head-on. The authors examine a pragmatic and increasingly influential strategy known as resource stratification, in which evidence-based clinical guidelines are adapted to the level of resources and health system capacity within a specific country or region. The approach was pioneered by the Breast Health Global Initiative, endorsed by the World Health Organization, and adopted by heavyweight bodies including the National Comprehensive Cancer Network and the American Society of Clinical Oncology. Now MASCC has developed and is piloting a standardized policy for resource-stratifying its own supportive care guidelines—and in doing so, it has run into five critical challenges that the paper dissects in detail.

The mechanics of resource stratification are conceptually elegant. The most common method, and the one MASCC has adopted, is to take a so-called parent guideline and adapt it to resource-constrained settings with input from experts. The resources required for a given intervention in a given context are identified and ranked by their relative importance and their impact on outcomes. Recommendations are then aligned to the highest achievable resource level in a setting, with hypothetical scenarios used to guide implementation. A staircase approach defines tiered resource levels—from basic to core to enhanced services—and recommends stepwise pathways for climbing from one tier to the next. Crucially, because these tiers are anchored to facility-level infrastructure and workforce availability rather than national income classification alone, the framework can also capture low-resource pockets within wealthy countries, which face challenges that are distinct from, rather than simply lesser versions of, those in low- and middle-income countries.

The first and perhaps most fundamental challenge is the evidence base itself. Resource stratification of a parent guideline typically relies on evidence generated in high-income countries, which may not adequately reflect the realities of low- and middle-income settings. Randomized controlled trials, the gold standard of clinical evidence, are largely conducted in wealthy nations and are typically designed to prioritize internal validity over external validity—the very quality that determines whether findings translate to a district hospital in a low-resource region. Compounding the problem, evidence appraisal systems that rank evidence using traditional quality hierarchies can inadvertently underrepresent cancer research from low- and middle-income countries, and high-impact journals have demonstrated editorial and review bias against submissions originating from those settings. The authors argue that while randomized trials and systematic reviews should remain the cornerstone of guideline development, a more inclusive approach to evidence synthesis is needed—one that considers observational research, qualitative studies, implementation science methods, and context-specific real-world data from local institutions, evaluated through transparent expert consensus.

Economics adds another layer of complexity. Robust cost-effectiveness analyses of supportive cancer care interventions in low- and middle-income countries are scarce, and applying results from wealthy countries to poorer ones is hazardous, because healthcare costs, financing structures, and the downstream consequences of care vary substantially between settings. Out-of-pocket expenses are often higher in low- and middle-income countries and can be financially catastrophic for patients and their families. This variation makes it difficult to calibrate the strength of recommendations based on cost alone, though partial economic evaluations, cost descriptions, and budget impact analyses from these settings may offer relevant evidence. Until more local research exists, the authors conclude, pragmatic assumptions and flexible interpretation of existing evidence are necessary to keep progress moving.

The second challenge is access. Availability of supportive care varies enormously across the globe and even within single countries, regions, and hospitals, meaning an intervention may be feasible in one setting but not another, even within the same resource category. Access itself is multidimensional, shaped by availability, affordability, acceptability, approachability, and cultural appropriateness. In many low- and middle-income countries, essential supportive care medications such as antiemetics, analgesics, and anxiolytics may not appear on national essential medicines lists, while unstable supply chains, regulatory hurdles, policy constraints, and workforce shortages hinder consistent delivery. The scale of the inequity is stark: 80 percent of the world’s population, mostly in low- and middle-income countries, consumes only 14 percent of the morphine used globally. MASCC research has also documented wide variation in the availability of optimal antiemetics for highly emetic chemotherapy protocols across Eastern European, Balkan, and Southeast Asian countries.

By explicitly weaving feasibility, availability, and affordability into guideline development, resource-stratified guidelines attempt to close the gap between what guidelines recommend and what clinicians can actually deliver. Rather than assuming universal access to optimal interventions, recommendations are tiered to reflect what is achievable, allowing evidence-based alternatives when standard options are inaccessible. Organizations such as MASCC cannot directly influence regulatory approvals, but through its global network it can document disparities, promote context-specific implementation strategies, support research on low-cost interventions, and disseminate evidence through international academic and policy channels. The underlying principle is that patients have the right to the best achievable quality of life, and that supportive care is integral to oncology practice rather than an optional add-on.

The third challenge is representation. Meaningful participation of individuals from low- and middle-income countries at every stage of guideline development, from topic selection through implementation, is essential for producing guidance that is relevant, feasible, and sustainable. Without it, panels lack the contextual knowledge to judge whether recommendations will work in diverse resource-constrained settings. Yet achieving such representation is difficult: competing clinical demands, limited internet connectivity, time zone differences, and a lack of institutional support all conspire against participation. The MASCC Antiemetic Guideline Group offers one pragmatic solution—a repository of names and contact details of interested clinicians in low- and middle-income countries, providing a mechanism for recruiting panel members with genuine lived clinical experience in resource-constrained environments. Flexible meeting formats, asynchronous collaboration, authorship and leadership recognition, and embedded capacity-building can further ease the barriers.

The fourth challenge is distinctive to supportive care: resource prioritization must be driven primarily by patient-reported outcomes. Where anticancer treatment typically prioritizes tumor control or survival, supportive care focuses on preventing and alleviating the physical, psychological, social, and practical consequences of cancer and its treatment. Outcomes such as symptom burden, function, distress, treatment adherence, caregiver burden, and patient experience are therefore central, not secondary, and must be weighed and ranked alongside cost, feasibility, and availability. The authors note that even in wealthy countries, high levels of unmet supportive care needs have persisted while anticancer therapies advanced rapidly, suggesting health systems systematically emphasize survival-focused biomedical treatment over quality of life. In resource-constrained settings, this imbalance may be even more pronounced, amplified by inadequate infrastructure, donor-driven agendas, and competing priorities.

The final challenge is perhaps the most subtle: misunderstanding of purpose. Clinicians and policymakers have expressed concern that resource-stratified guidelines could be misread as legitimizing substandard care, or as disincentivizing investment in international best-practice standards. Payers and regulatory bodies might even interpret them as justification for withholding optimal supportive care, even when such interventions are relatively low-cost and highly effective. In that scenario, the lowest resource tier risks becoming an endpoint rather than a stepping stone, perpetuating inequities in symptom control and quality of life. The authors insist that framing is everything: these guidelines are not cost-containment tools or ceilings on care, but instruments to optimize supportive care within existing constraints while defining practical pathways for system strengthening over time. Their intended purpose must be explicit—to support equitable improvement, not to legitimize inadequate care. As MASCC’s motto holds, supportive care makes excellent cancer care possible, in every resource setting on Earth.

Subject of Research: Resource stratification of supportive care clinical guidelines for cancer in low- and middle-income countries

Article Title: Navigating challenges in resource-stratification of supportive care clinical guidelines for cancer

Article References: Navigating challenges in resource-stratification of supportive care clinical guidelines for cancer. (n.d.). https://doi.org/10.1007/s00520-026-11330-5

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11330-5

Keywords: supportive care, clinical guidelines, resource stratification, cancer, low- and middle-income countries, health equity, MASCC, patient-reported outcomes, guideline adaptation, global oncology, access to medicines, health policy